Big Data, Digitalization, and Disruption: How are the headline trends of new technology and therapeutic innovation changing how we address today’s biggest healthcare challenges?
Chief Commercial Officer, Pear Therapeutics
Alex Waldron is Chief Commercial Officer at Pear Therapeutics. He is a senior level global bio/pharmaceutical business leader with 27+ years of experience with large pharmaceutical, fully integrated biopharmaceutical and startup organizations.
He has a proven record of building and leading business strategy and operations. In his career, Alex has driven enterprise value from portfolio strategy through to commercial launch. In previous roles, Alex has architected the structure and growth of several divisions at Biogen and helped to shape the emerging biosimilar market at Epirus Biopharmaceuticals. Alex has also worked in numerous commercial and operations roles at Genzyme, Astra Zeneca, Pfizer and Bristol-Myers Squibb.
Head of Marketing and Business Development, Philips Connected Care Sensing
Jaydeo Kinikar is currently Head of Marketing & Business Development for an innovation startup business unit within Philips Connected Care . This business is focused on building and commercializing digital health solutions across the care continuum, consisting of connected devices wearables, enterprise software, cloud based predictive analytics & clinical workflow transformation to address quadruple aim & value based care transformation. He has deep experience in establishing new business innovations with required competencies, mindset & organizational structure. He leverages unique combination of customer co-creation & design thinking methodologies, digital solutions transformation & commercial go-to-market strategies to develop disruptive innovations for customers’ evolving needs.
Dr. Jon Bloom
Chief Executive Officer, Podimetrics
Dr. Jon Bloom is a board-certified physician and entrepreneur with over 10 years in technology development, patient monitoring, biomedical research, and healthcare delivery. He presently serves as Chief Executive Officer of Podimetrics, a medical device and services company he co-founded in 2011 while a student at the MIT Sloan School of Management focused on the early detection and prevention of diabetic foot complications.
Prior to MIT, Dr. Bloom served as a Clinical Assistant Professor and Staff Anesthesiologist at the University of Pittsburgh Medical Center. He additionally served as the Director of Global Medical Affairs for Covidien's Respiratory and Monitoring Solutions division in Boulder, Colorado. Dr. Bloom is a Diplomate of the American Board of Anesthesiology, completing residency at the Massachusetts General Hospital. He has co-authored over 20 peer-reviewed publications with a primary focus on healthcare economics and perioperative complications. Prior to his career in medicine Dr. Bloom studied cytochrome P450 drug metabolism at The Scripps Research Institute.
Founder and CEO, Wellist
As the Founder and CEO of Wellist, Ashley combines her passion for improving the lives of patients with deep experience in strategic planning and business development. Founded in 2013, Wellist now works with Mass General Hospital Cancer Center, Beth Israel Deaconess Medical Center MemorialCare Health System, and UPMC Hillman Cancer Center, with combined patient populations of over 120,000. Wellist has received numerous awards including a Silver Stevie Award for Company of the Year, "Innovative Tech of the Year - Healthcare Tech" from MassTLC, was named a Rock Health/Top 50 in Digital Health, received the "Diversity Leadership Award: Start-Up", and was chosen as a "50 on Fire", which recognizes "the city's inventors, disruptors, luminaries, and newsmakers". Ashley was also recently named a winner of Med Tech’s 40 under 40 Healthcare Innovators.
Co-Founder, Novartis Biome
Dr. Lynda Chin
Founder and CEO, Apricity Health
An elected member of the National Academy of Medicine, the Association of American Physicians, and the American Society for Clinical Investigation, Dr. Chin is a world renowned cancer genomic scientist, a frequent speaker in national and international conferences including TEDMed, who has authored or co-authored hundreds of peer-reviewed publications. At Dana-Farber Cancer Institute where she was a professor at Harvard Medical School and a senior associate member at the Broad Institute of MIT and Harvard, Dr. Chin conducted research spanning mouse models of human cancers, cancer genomics, functional genomics and personalized medicine. Outside of her laboratory, Dr. Chin held multiple leadership positions in The Cancer Genome Atlas (TCGA) project in the U.S., including serving on the executive subcommittee and leading the development of Firehose pipeline as co-PI at the Broad Institute. Internationally, Dr. Chin has been active in the International Cancer Genome Consortium since its inception, currently sitting on the ICGC-ARGO Steering Committee and chairing its Phenomics Working Group. Read more.
Managing Partner, 20/20 HealthCare Partners
Hillel Bachrach is a dynamic executive entrepreneur, with more than 40 years of hands-on experience managing and directing all aspects of the commercial global introduction of new, innovative, and revolutionary medical technologies. After a successful career as an entrepreneur, starting and exiting, IPO, Strategic & Sponsors’ buyouts, currently, Mr. Bachrach is the managing partner of 20/20 HealthCare Partners, LLC, a global investment entity he founded in 2005. As active investors, 20/20 HCP provides equity financing for promising growth businesses as well as for public offerings, buyouts or re-capitalizations of companies specializing in med-tech healthcare, diagnostic imaging hardware and software, HCIT and lately advanced Bio-Tech technologies. Read more.